Treatment Patterns in the Management of Multiple Myeloma in a Colombian HMO During 2015–2023: A Real-World Data Study

Author(s)

Farley Gonzalez, MSc1, Leonardo Jose Enciso Olivera, MD1, Juan Manuel Reyes Sanchez, MSc2, Jair A. Arciniegas, MSc2, Luz E. Perez Jaramillo, MSc1, Andreina J. Alamo, BSc2, Carlos Bello, Pharm1, Mónica García, MSc2, Brigitte Alejandra Alarcon, MD2, Jhon E. Bolaños, MSc, MD1;
1Biociencias-Sura, Medellín, Colombia, 2Pfizer, Bogotá, Colombia

Presentation Documents

OBJECTIVES: To identify treatment patterns in the management of multiple myeloma (MM) in a Colombian Health Maintenance Organization (HMO) between 2015-2023.
METHODS: A retrospective, descriptive cohort study of MM patients from 2015 to 2023 was conducted. Patients with the ICD-10 code C90.0 were included. The index date was when MM was diagnosed, and patients were followed until death, insurance discontinuation, or December 31, 2023, whichever occurred first. Demographics, treatment, and medical care were assessed at the index and during follow-up. Data were extracted from HMO administrative health records. Patients who achieved strict complete response, complete response, very good partial response or partial response were classified as responders.
RESULTS: N=700 patients were included. At diagnosis, approximately 50.5% of these patients presented arterial hypertension, with a median age of 64 years (IQR 16, Q1-Q3: 55-71) and more than half (51.3%) of the patients were at III stage (A or B) of the Durie-Salmon classification. At the last contact, 65% were alive, 51.3% had registered a complete response, and 23.1% had progressed. The most common first-line (1L) treatment was CyBorD (Cyclophosphamide+bortezomib+ dexamethasone) (44.9%), where 85.0% were responders and 13.4% progressed. At 2L (513 patients), autologous transplantation (AT) was the preferred option (n=229, 44.6%); the majority of patients (94.8%) were responders and 5.2% progressed. At 3L (271 patients), AT (18.5%), and lenalidomide-bortezomib-dexamethasone (RVd) (12.5%) were the most common treatment strategies. The proportion of patients with later line data was small (4L = 18.4%, 5L = 8%, 6L = 2.7%, and 7L = 0.6%).
CONCLUSIONS: Patients were in later stages of the disease according to Durie-Salmon, most of them achieved complete response at final contact, and CyBorD was the preferred treatment for first line and AT for the second and third lines.

Conference/Value in Health Info

2025-05, ISPOR 2025, Montréal, Quebec, CA

Value in Health, Volume 28, Issue S1

Code

HSD35

Topic

Health Service Delivery & Process of Care

Disease

SDC: Oncology

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×